Medication Guide ENHERTU® (en-HER-too) (fam-trastuzumab deruxtecan-nxki) for injection What is the most important information I should know about ENHERTU? ENHERTU can cause serious side effects, including: Lung problems that may be severe, life-threatening or that may lead to death. ...
For injection: 100 mg of fam-trastuzumab deruxtecan-nxki as a white to yellowish white lyophilized powder in a single-dose vial for reconstitution and further dilution Storage And Handling ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection is a white to yellowish white lyophilized powder su...
Generic Name:fam-trastuzumab deruxtecan-nxki for injection Brand Name:Enhertu Drug Class:,Antineoplastic Topoisomerase Inhibitors,Antineoplastics, Anti-HER2 Medical Editor:John P. Cunha, DO, FACOEPLast updated on RxList:4/12/2024 homedrugs a-z listenhertu (fam-trastuzumab deruxtecan-nxki for ...
药品别名: 注射用德曲妥珠单抗/优赫得/優赫得/(fam-trastuzumab deruxtecan-nxki/Trastuzumab Deruxtecan for Injection/Enhertu 剂型: 注射剂 规格: 100mg/瓶 有效期: 4年 原研药厂: 第一三共株式会社(Daiichi Sankyo) 产地: 德国 价格: 详询客服 上市版本: 点击查看 ...
Fam-trastuzumab deruxtecan is given as an infusion into a vein. A healthcare provider will give you this injection.Fam-trastuzumab deruxtecan is usually given once every 3 weeks in a 21-day treatment cycle. Your doctor will determine how long to treat you with fam-trastuzumab deruxtecan....
Trastuzumab deruxtecan is an antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer. Brand Names Enhertu Generic Name Trastuzumab deruxtecan DrugBank Accession Number DB14962 Background Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomeras...
Daiichi Sankyo Inc. Enhertu (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use. Prescribing Information. Basking Ridge, NJ: Daiichi Sankyo; revised April 2024. Keown A. Enhertu snags FDA approval for HER2-positive gastric cancer patients. BioSpace, January 18, 2021. Available...
Before February 2023, there were up to six entities of biological agents (pertuzumab, trastuzumab emtansine, inetetamab, disitamab vedotin, trastuzumab deruxtecan, and margetuximab) on the market with indications for HER2-positive breast cancer and gastric cancer, akin to trastuzumab. Among these...
Before February 2023, there were up to six entities of biological agents (pertuzumab, trastuzumab emtansine, inetetamab, disitamab vedotin, trastuzumab deruxtecan, and margetuximab) on the market with indications for HER2-positive breast cancer and gastric cancer, akin to trastuzumab. Among these...
Brand and Other Names:Enhertu, fam-trastuzumab deruxtecan-nxki Classes:Antineoplastics, Anti-HER2; Antineoplastics, Monoclonal Antibody; Antineoplastics, Topoisomerase Inhibitors Print Dosing & Uses AdultPediatric Dosage Forms & Strengths injection, lyophilized powder for reconstitution ...